VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Launched by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) · Oct 19, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the effectiveness of two medications, VIR-2218 and peginterferon alfa-2a, for treating chronic hepatitis B, a viral infection that affects the liver. The goal is to see how well these treatments work in people who have mild or inactive hepatitis B. To participate, individuals must be between 18 and 65 years old and meet certain health criteria, such as having specific blood test results that indicate they have a manageable form of the infection.

Participants in the study will receive monthly injections of VIR-2218 for six months and weekly injections of peginterferon for the same period. They will be closely monitored through blood tests, liver scans, and two short hospital stays for special tests on their liver. After the treatment phase, participants will continue to have follow-up visits for several months to track their health. This trial is important because chronic hepatitis B can lead to serious liver problems, and new treatment options are needed.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• • 1. Age \>=18-65 years
• • 2. HBsAg positive with a level \<2,000 IU/mL at the time of screening
• • 3. Hepatitis B e antigen negative
• • 4. HBV DNA levels \<10,000 IU/mL on two occasions at least 24 weeks apart with the second being at time of screening
• • 5. ALT level \<=2 ULN (using sex-specific cut-offs of normal 35 U/L for males and 25 U/L for females) based on at least two determinations taken at least 24 weeks apart with the second being at time of screening
• EXCLUSION CRITERIA:
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • 1. Pregnancy or lactation
• • 2. For women of childbearing potential, inability, or unwillingness to use highly effective contraception during study drug dosing and for an additional 24 weeks after the end of study drug administration.
• • 3. For males of reproductive potential: Unable or unwilling to use condoms consistently in addition to female partner using another adequate contraceptive method to ensure effective contraception with partner during study participation and for an additional 24 weeks after the end of study medication administration. Patients who have underwent surgical sterilization (vasectomy) will still require female partner to utilize an additional adequate contraception method.
• • 4. Known history of hypersensitivity or contraindication to an siRNA, oligonucleotide, or GalNAc or any interferon product
• • 5. Current use of oral theophylline and methadone
• • 6. Any treatment for HBV within the last 24 weeks
• • 7. Prior exposure to a siRNA
• • 8. Co-infection with HDV as defined by the presence of anti-HDV in serum.
• • 9. Co-infection with HCV as defined by the presence of anti-HCV and HCV RNA in serum.
• • 10. Co-infection with HIV as defined by the presence of anti-HIV in serum
• • 11. Cirrhosis either diagnosed by a prior liver biopsy at any time or, if not available, by a transient elastography score \>13 kPa
• • 12. Decompensated liver disease as defined by serum bilirubin \>2.5 mg/dL (with direct bilirubin \> 1.5 mg/dL), prothrombin time of greater than 2 seconds prolonged, a serum albumin of less than 3.5 g/dL, or a history of ascites, variceal bleeding or hepatic encephalopathy
• • 13. Hepatocellular carcinoma (HCC), or the presence of a mass on imaging studies of the liver that is suggestive of HCC, or an alpha-fetoprotein level of greater than 500 ng/mL
• • 14. Presence of other causes of liver disease, (i.e. hemochromatosis, Wilson disease, alcoholic liver disease, severe steatosis, alpha-1-anti-trypsin deficiency)
• • 15. A history of solid organ or bone marrow transplant
• • 16. Any current medical condition requiring the chronic use of more than 10 mg of prednisone (or its equivalent) daily or biologics (e.g. monoclonal antibody, interferon) within 3 months of screening.
• • 17. Significant systemic illness other than liver diseases including congestive heart failure, renal failure, chronic pancreatitis and diabetes mellitus with poor control (hemoglobin A 1C (HgbA1C \>8.5)), that in the opinion of the investigator may interfere with therapy.
• • 18. eGFR \< 60 ml/min, serum creatinine \> 1.3 mg/dl
• • 19. Platelet count \<90 mm3/dL
• • 20. Hgb \<12 g/dL for males and \<11 g/dL for females
• • 21. White Blood cell count \< 2500 cells/mm3
• • 22. Neutrophil count \< 1500 cell/mm3 (or \< 1000 cell/mm3 if considered a physiological variant in a subject of African descent)
• • 23. Active ethanol/drug abuse/psychiatric problems such as major depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality disorder that, in the investigator s opinion, might interfere with participation in the study.
• • 24. History of malignancy or treatment for a malignancy within the past 3 years (except adequately treated carcinoma in situ or basal cell carcinoma of the skin).
• • 25. History of immune-mediated disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, sarcoidosis, psoriasis of greater than mild severity, autoimmune uveitis), or cerebrovascular, chronic pulmonary or cardiac disease associated with functional limitation, retinopathy, uncontrolled thyroid disease, (TSH \>10 or \<0.4mU/L) or uncontrolled seizure disorder, as determined by a study physician.
• • 26. Use of another investigational agent within 90 days of screening
• • 27. Use of any prohibited immunosuppressants (except short term use of prednisone as a steroid burst \[\<= 1 week of use\]) or cytotoxic medications
• • 28. Presence of conditions that, in the opinion of the investigators, would not allow the patient to be followed in the current study.
• • 29. Inability of subject to understand and the unwillingness to sign a written informed consent document